Welcome to webinar
CDK 4/6 inhibitors in clinical practice – learnings from real-world evidence
CDK 4/6 inhibitors in combination with endocrine therapy is an established treatment strategy in metastatic luminal breast cancer. However, there are still various aspects regarding dosing and management of adverse events related to CDK 4/6 inhibitors that can be a challenge in everyday clinical practice. This Webinar will use real-world evidence (RWE) to discuss these aspects and how to think as a clinician when patients are treated with CDK 4/6 inhibitors.
You will be able to submit questions to the speaker during the webinar.
Information regarding Privacy Notice, click here.
Lecture
Antonios Valachis,
Oncologist and Ass. Prof. Örebro University, Sweden
PP-IBR-SWE-0714, Sept-2022
If you have any question regarding the webinar please contact:
Daniel Nyqist
Senior Medical Affairs Scientist
Phone: + 46 76-889 26 97
daniel.nyqvist@pfizer.com